Rallybio Corp
General ticker "RLYB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $48.0M
Rallybio Corp does not follow the US Stock Market performance with the rate: -29.3%.
Estimated limits based on current volatility of 4.3%: low 0.91$, high 0.99$
Factors to consider:
- Current price 59.5% below estimated low
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [3.04$, 7.82$]
- 2023-12-31 to 2024-12-30 estimated range: [2.25$, 5.91$]
Short-term RLYB quotes
Long-term RLYB plot with estimates
Financial data
| YTD | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $25.30MM | $45.65MM | $67.88MM |
| Operating Income | $-25.30MM | $-45.65MM | $-67.88MM |
| Non-Operating Income | $0.36MM | $0.14MM | $2.31MM |
| Interest Expense | $0.05MM | $0.01MM | $0.00MM |
| R&D Expense | $17.63MM | $26.91MM | $40.69MM |
| Income(Loss) | $-24.94MM | $-45.51MM | $-65.58MM |
| Taxes | $-0.01MM | $0.00MM | $0.00MM |
| Profit(Loss) | $-24.93MM | $-45.51MM | $-65.58MM |
| Stockholders Equity | $136.00MM | $175.60MM | $169.32MM |
| Assets | $141.86MM | $182.19MM | $180.44MM |
| Operating Cash Flow | $-22.04MM | $-45.53MM | $-57.28MM |
| Capital expenditure | $0.14MM | $0.33MM | $0.05MM |
| Investing Cash Flow | $-2.07MM | $-2.33MM | $-112.17MM |
| Financing Cash Flow | $144.89MM | $82.97MM | $51.08MM |
| Earnings Per Share* | $-0.78 | $-1.46 | $-2.09 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.